General information

Announcements(0)

Overview

Manual for Online Meeting

Participant Registration

Abstract Submission (Oral/Poster Presentation)

General information 2

Abstract Submission (Late-Breaking Session)

Program

Sessions

Search presentations

pharm141_en.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

A password that applicants have been notified of is required to view abstracts. If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts. We will reply after confirming that you were a participant. Thank you for your understanding.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Profile management

Announcements

Bookmark

Download PDF for print

Timetable

Anti-tumor activity of arsenic compounds and its potential novel application in clinics

Drug discovery by focusing on the new chemical modalities, including antibodies, nucleic acids, cellular medicines and gene therapy, have been intensively investigated in recent years. On the other hand, the presence of low-molecular-weight (small-molecule) drugs seems to be getting smaller both in academia and in pharmaceutical companies. However, low-molecular-weight drugs have advantages in production cost and quality control, and therefore the importance of small-molecule compounds in drug discovery is not decreased. In this symposium, we will focus on the novel strategies for drug discovery with elements chemistry approaches. Though the conventional drugs consist of the common elements such as CHNOS and halogens, recently, application of various elements such as boron, silicon, and deuterium for drug discovery is coming on the limelight. Various ‘elements medicinal chemistry’ researches focusing on deuterium, boron, silicon, and arsenic, as well as the development of borofalan (10B) (Steboronine), the world’s first BNCT (boron neutron capture therapy) drug, will be presented. Development of new methodology and novel chemical modalities of small-molecules for drug discovery will be also discussed.

Developing the next generation small-molecule pharmaceuticals using a wide variety of elements

The 141st Annual Meeting of the Pharmaceutical Society of Japan (Hiroshima)

Presentation Information

[S11-5]Anti-tumor activity of arsenic compounds and its potential novel application in clinics

Password required to view